Company Overview: TransMedics Group, Inc. (NASDAQ: TMDX) is a commercial-stage medical technology company that is disrupting the organ transplant industry by replacing traditional "cold storage" with a system that mimics the human body's natural state. This Report covers the Price Action, Technical Indicators Analysis along with the Support Levels, Resistance Levels, and Recommendations on this stock.

Financial Performance & Guidance: TransMedics reported total revenue of $143.8 million in Q3 2025, representing approximately 32% year-over-year growth, driven by strong demand across its organ transplant segments. Net income rose sharply to $24.3 million compared with $4.2 million in Q3 2024, reflecting significant improvement in profitability. Diluted earnings per share came in at $0.66, exceeding the analyst consensus estimate of about $0.37 by roughly $0.29. Gross margin expanded to 59% from 56% in the prior-year quarter, supported by higher utilization and operational efficiencies, while operating expenses increased modestly to $61.3 million as the company continued investing in research and development and organizational expansion.

Performance was broad-based across all organ segments, with particularly strong growth in liver and heart revenue. The company ended the quarter with $466.2 million in cash and equivalents, reinforcing a solid liquidity position. Reflecting confidence in ongoing execution and demand trends, TransMedics raised its full-year 2025 revenue guidance to a range of approximately $595 million to $605 million.

TMDX’s Technical Analysis:

Past performance is not a reliable indicator of future performance.